LMAT

LeMaitre Vascular Inc

Add to Watchlist

Advanced Chart

86.610

-1.94(-2.191%)1D

Line

Candle

YTD

High

88.485

Open

87.590

VWAP

87.36

Vol

168.60K

Mkt Cap

1.96B

Low

86.440

Amount

14.73M

EV/EBITDA(TTM)

27.89

Total Shares

22.45M

1.81B

EV/OCF(TTM)

30.79

P/S(TTM)

8.45

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

62.18M

+13.43%

0.564

+15.05%

64.32M

+15.44%

0.631

+28.83%

66.07M

+10.36%

0.588

+22.57%

Estimates Revision

The market is revising Upward the revenue expectations for LeMaitre Vascular, Inc. (LMAT) for FY2025, with the revenue forecasts being adjusted by 1.94% over the past three months. During the same period, the stock price has changed by 2.67%.

Revenue Estimates for FY2025

Revise Upward

+1.94%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5.02%

In Past 3 Month

Stock Price

Go Up

+2.67%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast LMAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMAT is 102.67 USD with a low forecast of 95.00 USD and a high forecast of 113.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 86.610

Low

95.00

Averages

102.67

High

113.00

Current: 86.610

Low

95.00

Averages

102.67

High

113.00

Barrington

Michael Petusky

Market Perform

Outperform

upgrade

$95

2025-08-06

Reason

Barrington

Michael Petusky

Price Target

$95

2025-08-06

upgrade

Market Perform

Outperform

Reason

Barrington analyst Michael Petusky upgraded LeMaitre to Outperform from Market Perform with a $95 price target. The company reported strong Q2 results with 15% organic growth and 25% operating margins, the analyst tells investors in a research note. The firm now has conviction that LeMaitre will have a good second half of 2025 and even better 2026.

Barrington Research

Michael Petusky

Buy

Hold

Downgrades

n/a

2025-02-28

Reason

Barrington Research

Michael Petusky

Price Target

n/a

2025-02-28

Downgrades

Buy

Hold

Reason

Citizens Capital Markets

Daniel Stauder

Strong Buy

Maintains

$105 → $110

2025-02-28

Reason

Citizens Capital Markets

Daniel Stauder

Price Target

$105 → $110

2025-02-28

Maintains

Strong Buy

Reason

Lake Street

Brooks O'Neil

Strong Buy

Maintains

$105 → $110

2025-02-28

Reason

Lake Street

Brooks O'Neil

Price Target

$105 → $110

2025-02-28

Maintains

Strong Buy

Reason

Wells Fargo

Nathan Treybeck

Hold

Initiates

$95

2025-02-13

Reason

Wells Fargo

Nathan Treybeck

Price Target

$95

2025-02-13

Initiates

Hold

Reason

Wells Fargo analyst Nathan Treybeck initiated coverage of LeMaitre with an Equal Weight rating and $95 price target. The firm believes the company's high-single-digit pricing contribution to 2025 organic growth is already priced into the stock. LeMaitre is a leading player in several niche open vascular surgery markets, but the shares offer limited upside from current levels, the analyst tells investors in a research note. Wells says a key debate in the stock is how long the recent price floor adjustments can sustain above-historical pricing growth.

See All Ratings

Valuation Metrics

The current forward P/E ratio for LeMaitre Vascular Inc (LMAT.O) is 35.72, compared to its 5-year average forward P/E of 39.97. For a more detailed relative valuation and DCF analysis to assess LeMaitre Vascular Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

39.97

Current PE

35.72

Overvalued PE

45.16

Undervalued PE

34.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

23.92

Current EV/EBITDA

23.23

Overvalued EV/EBITDA

27.54

Undervalued EV/EBITDA

20.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

7.14

Current PS

86.61

Overvalued PS

11.32

Undervalued PS

2.96